The firm is accused of for printing higher MRP for hospitals and lower for open market
Competition Commission India (CCI) has ordered an investigation against Becton Dickinson India for alleged anti-competitive practices with respect to healthcare services.
Becton Dickinson, an MNC that makes disposable syringe under the brand name 'Emerald', has been accused for selling disposable syringe on higher MRP to hospitals and sell same product with lower price in open market.
According to Mr Bejon Mishra , a consumer activist from the organisation, Partnership for Safe Medicine said, "Such kind of collusion between manufacturers and importers and hospitals of variable and arbitrary price fixation to fleece consumers indicates the need for government to step in to protect consumers with a price capping mechanism or a taxation by importer or manufacturer linked the MRP as these innocent gullible consumers have no idea about prices of competing medical devices and rely solely on the printed price or their faith in the hospital or doctor."
The Commission has ordered a detailed probe by its investigation arm Director General (DG) after finding "prima facie" case of contravening competition norms.
According to the Commission, the informant is primarily aggrieved by the conduct of the opposite parties in charging a higher MRP for disposable syringe manufactured by Becton Dickinson India (OP 1) and brought from an in house pharmacy located within the hospital network of Max Super Speciality Hospital (OP 2).